title: Enhanced myopathy following administration of hypolipidemic agents under urethane anesthesia.
abstract: The enhanced effect of urethane anesthesia on the serum creatine kinase (CPK) level following administration of hypolipidemic agents was examined to develop a convenient experimental screening method for drug-induced myopathy. After oral administration of a hypolipidemic agent to rats, 25% urethane solution was infused intravenously at a very low rate using a microinfusion pump. Blood samples were collected 7 h after drug administration and the risk of myopathy was evaluated based on the CPK level. When bezafibrate (BF), simvastatin (SV), or pravastatin (PV) (50-500 mg/kg) was orally administered under urethane infusion, enhanced elevation of the serum CPK level was observed dose dependently for BF and SV, but not for PV. The elevation of serum CPK was much higher with BF than with SV or PV. In addition, when SV or PV (50-500 mg/kg) was coadministered with 50 mg/kg of BF, there was a striking increase in the serum CPK level as compared with the drug alone. Without urethane infusion, no significant elevation in serum CPK level was observed even at a high dose of these hypolipidemic agents. These phenomena suggest that the urethane anesthesia enhanced the elevation of the serum CPK level following administration of hypolipidemic agents. We propose that this method is a simple and speedy screening test for drug-induced myopathy.
authors.affiliation: Faculty of Pharmaceutical Sciences, Mukogawa Women's University, Koshien, Nishinomiya, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Nakai
authors.forename: M
authors.initials: M
authors.lastname: Nishikata
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Ichikawa
authors.forename: K
authors.initials: K
authors.lastname: Matsuyama
mesh_terms: D000758:Anesthesia; D000818:Animals; D001629:Bezafibrate / Q000009:adverse effects; D002118:Calcium / Q000378:metabolism; D003402:Creatine Kinase / Q000097:blood; D000960:Hypolipidemic Agents / Q000009:adverse effects*; D008148:Lovastatin / Q000009:adverse effects / Q000031:analogs & derivatives; D008297:Male; D009135:Muscular Diseases / Q000139:chemically induced*; D017035:Pravastatin / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D019821:Simvastatin; D014520:Urethane
chemical_list: D000960:Hypolipidemic Agents; D014520:Urethane; D008148:Lovastatin; D019821:Simvastatin; D003402:Creatine Kinase; D017035:Pravastatin; D002118:Calcium; D001629:Bezafibrate